Most Recent
The close relationship between regulator action over corporate wrongdoing and private enforcement is an established and powerful means of recovering compensation for victims of corporate misconduct. Increased cooperation between regulators and litigants in class actions would remove a number of substantial barriers to private enforcement action, writes Slater and Gordon lawyer Caitlin Baker.
The High Court is poised this week to issue its judgment in a case challenging the validity of common fund orders in class actions, a ruling that could see litigation funding commission rates creep back up after hitting record lows.
IP boutique Griffith Hack will soon have around 80 practicing lawyers when it absorbs Australia's oldest specialist intellectual property firm Watermark next year.
Qube has filed a misuse of market power case against the operator of the Port of Newcastle for allegedly forcing the logistics giant to pay for equipment it needs to provide dry bulk unloading services at the port.
The National Australia Bank and insurer MLC have agreed to pay $49.5 million to settle a class action over allegedly worthless credit card insurance.
Google's promise to shield users' health data after its planned $3 billion acquisition of fitness tech company Fitbit should be taken with a grain of salt, ACCC chairman Rod Sims said Tuesday.
Garmin has reached a settlement in a competition case brought by its former exclusive Australian distributor alleging the GPS technology giant misused its market power after the supplier refused to give up its five best customers.
A sizeable group of employment lawyers from K&L Gates has parted ways with the US legal giant to set up its own specialist shop, shaking up the market for employment law services in Australia.
The Supreme Court of Victoria has considered whether an insured buyer under a warranty and indemnity policy is entitled to indemnity from an insurer when it relied on income and liability warranties in a share sale agreement and those warranties were breached, a case that provides welcome guidance on the contractual interpretation of W&I policies, writes Justin McDonnell and Rebecca LeBherz of King & Wood Mallesons.
Australian drug maker Juno Pharmaceuticals has hit back at claims it is infringing the patent for US-based Pfizer's post-operative pain killer Dynastat, saying the patent is invalid.